Posters and mini-orals include another VEGF bispecific.
ApexOnco Front Page
Recent articles
Interius, one of the most advanced players, will cost $350m.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
AVZO-023 follows AVZO-021 into clinical trials.
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
The move follows promising but early data presented at ASCO.
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
